Compare INSE & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSE | CRDL |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 154.1M |
| IPO Year | 2014 | 2017 |
| Metric | INSE | CRDL |
|---|---|---|
| Price | $6.99 | $1.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $14.00 | $8.50 |
| AVG Volume (30 Days) | 87.4K | ★ 693.8K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $199,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.25 | N/A |
| 52 Week Low | $6.11 | $0.88 |
| 52 Week High | $9.95 | $1.71 |
| Indicator | INSE | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 49.53 |
| Support Level | $6.70 | $0.95 |
| Resistance Level | $7.64 | $1.43 |
| Average True Range (ATR) | 0.32 | 0.11 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 43.52 | 12.79 |
Inspired Entertainment Inc is a gaming technology company, supplying content, platform and other products and services to licensed online and land-based lottery, betting and gaming operators of various countries through a range of distribution channels, on a business-to-business basis. The company provides digital gaming solutions (i) on its own proprietary and secure network, which accommodates a wide range of devices, including land-based gaming machine terminals, mobile devices and online computer applications, and (ii) through third party networks. It operates in four business segments: Gaming, Virtual Sports, Interactive and Leisure. The majority of revenue is derived from the Leisure Segment, which includes the supply of the gaming and amusement machines.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.